FindTrial
Sign In

polyvalent antigen-KLH conjugate vaccine

BIOLOGICAL2 trials

Sponsors

Gynecologic Oncology Group

Conditions

Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity CancerStage IA Fallopian Tube CancerStage IA Ovarian CancerStage IB Fallopian Tube CancerStage IB Ovarian CancerStage IC Fallopian Tube Cancer

Phase 2

OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
CompletedNCT00857545
Gynecologic Oncology GroupStage IA Fallopian Tube Cancer, Stage IA Ovarian Cancer, Stage IB Fallopian Tube Cancer +21
Start: 2010-07-31Updated: 2017-09-13

Phase 3

Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission
WithdrawnNCT00693342
Gynecologic Oncology GroupFallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Updated: 2020-02-24

Related Papers

A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study
Gynecologic Oncology2019-10-2226 citations
A phase II randomized, double-blind trial of a polyvalent vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian (EOC), fallopian tube, or peritoneal cancer who are in second or third complete remission.
Journal of Clinical Oncology2016-05-20